Results 171 to 180 of about 10,350,043 (423)

Surfaceome: a new era in the discovery of immune evasion mechanisms of circulating tumor cells

Molecular Oncology, EarlyView.
In the era of immunotherapies, many patients either do not respond or eventually develop resistance. We propose to pave the way for proteomic analysis of surface‐expressed proteins called surfaceome, of circulating tumor cells. This approach seeks to identify immune evasion mechanisms and discover potential therapeutic targets. Circulating tumor cells (
Doryan Masmoudi, Jérome Vialaret, Christophe Hirtz, Catherine Alix‐Panabières   +3 more
wiley   +1 more source

The Molecular Recognition of Lurasidone by Human Serum Albumin: A Combined Experimental and Computational Approach

Molecules
Lurasidone (LUR) is an antipsychotic drug whose interaction with human serum albumin (HSA) plays a crucial role in its pharmacokinetic and pharmacodynamic properties.
Nevena Živković, Emina Mrkalić, Ratomir Jelić, Jovica Tomović, Jadranka Odović, Marina Ćendić Serafinović, Miroslav Sovrlić   +6 more
doaj   +1 more source

The treatment of Plasmodium falciparum-infected erythrocytes with chloroquine leads to accumulation of ferriprotoporphyrin IX bound to particular parasite proteins and to the inhibition of the parasite's 6-phosphogluconate dehydrogenase

Parasite, 2003
Ferriprotoporphyrin IX (FPIX) is a potentially toxic product of hemoglobin digestion by intra-erythrocytic malaria parasites. It is detoxified by biomineralization or through degradation by glutathione.
Famin O., Ginsburg H.
doaj   +1 more source

The Relation of Protein Binding to the Pharmacology and Antibacterial Activity of Penicillins X, G, Dihydro F, and K [PDF]

, 1947
Ralph Tompsett, SELMA M. SHULTZ, Walsh McDermott   +2 more
openalex   +1 more source

A Highly Sensitive Plant Hybrid Protein Assay System Based on the \u3cem\u3eSpm\u3c/em\u3e Promoter and TnpA Protein for Detection and Analysis of Transcription Activation Domains [PDF]

, 1996
TnpA is a multifunctional DNA binding protein encoded by the maize Suppressor-mutator (Spm) transposable element. TnpA is required for transposition and is a repressor of the unmethylated Spm promoter.
Fedoroff, Nina V., Raina, Ramesh, Schläppi, Michael   +2 more
core   +1 more source

Clinical applications of next‐generation sequencing‐based ctDNA analyses in breast cancer: defining treatment targets and dynamic changes during disease progression

Molecular Oncology, EarlyView.
Circulating tumor DNA (ctDNA) offers a possibility for different applications in early and late stage breast cancer management. In early breast cancer tumor informed approaches are increasingly used for detecting molecular residual disease (MRD) and early recurrence. In advanced stage, ctDNA provides a possibility for monitoring disease progression and
Eva Valentina Klocker, Samantha Hasenleithner, Rupert Bartsch, Simon P. Gampenrieder, Daniel Egle, Christian F. Singer, Gabriel Rinnerthaler, Michael Hubalek, Katja Schmitz, Zsuzsanna Bago‐Horvath, Andreas Petzer, Sonja Heibl, Ellen Heitzer, Marija Balic, Michael Gnant   +14 more
wiley   +1 more source

WideDTA: prediction of drug-target binding affinity [PDF]

arXiv, 2019
Motivation: Prediction of the interaction affinity between proteins and compounds is a major challenge in the drug discovery process. WideDTA is a deep-learning based prediction model that employs chemical and biological textual sequence information to predict binding affinity.
arxiv  

STUDIES IN SERUM ELECTROLYTES. XV. THE CALCIUM-BINDING PROPERTY OF THE SERUM PROTEINS (MULTIPLE MYELOMA, LYMPHOGRANULOMA VENEREUM AND SARCOIDOSIS) [PDF]

, 1948
Arnold J. Rawson, F. William Sunderman
openalex   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Predicting Protein Binding of Drugs Using Abraham Parameters: Effect of Ionization

Journal of Mazandaran University of Medical Sciences, 2019
Background and purpose: Protein binding (PB) is an important pharmacokinetic parameter in drug discovery and development. In past years Abraham parameters were used to predict some physicochemical and pharmacokinetic properties of drugs.
Shadi Shayanfar, Ali Shayanfar
doaj